Drugs that contain Dexlansoprazole

1. List of Dexilant drug patents

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(3 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(6 months from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(6 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 13 days from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 13 days from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(2 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(3 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(3 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(6 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(7 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(8 years from now)

Market Authorisation Date: 30 January, 2009

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagi...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

DEXILANT family patents

35

United States

23

Japan

12

European Union

9

Korea, Republic of

8

Canada

7

Argentina

7

Spain

6

China

5

Denmark

5

Australia

5

Brazil

5

Portugal

5

Cyprus

4

Mexico

4

Hong Kong

4

Malaysia

4

Taiwan, Province of China

3

Israel

3

Russia

3

Norway

3

Costa Rica

3

Peru

3

Poland

3

New Zealand

2

South Africa

2

Slovenia

2

Singapore

OA

1

OA

1

Austria

1

Belgium

1

Hungary

1

Morocco

1

Germany

1

Colombia

1

Chile

2. List of Dexilant Solutab drug patents

DEXILANT SOLUTAB's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(3 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(6 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 13 days from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(2 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(5 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(5 years from now)

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

30

United States

21

Japan

10

European Union

8

Argentina

7

Korea, Republic of

7

Canada

5

Australia

5

Brazil

5

Spain

5

Peru

5

Taiwan, Province of China

5

China

4

Mexico

4

Costa Rica

4

Malaysia

4

New Zealand

3

South Africa

3

Denmark

3

Hong Kong

3

Norway

3

Portugal

3

Cyprus

3

Poland

2

Israel

2

Slovenia

2

Morocco

2

Chile

OA

1

OA

1

Austria

1

Belgium

1

Hungary

1

Uruguay

1

Germany

1

Colombia

1

Singapore

1

Dominican Republic

1

Ecuador

1

Georgia

1

Ukraine

EA

1

EA

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic